title: The effects of methylene blue on renal scarring due to pyelonephritis in rats.
abstract: The aim of this study was to evaluate the efficiency of methylene blue (MB) in preventing renal scar formation after the induction of pyelonephritis (PNP) in a rat model with delayed antimicrobial therapy. An inoculum of the K-12 strain of Escherichia coli was injected into both kidneys. Control groups received isotonic saline instead of bacterial solution. Four equal groups were then formed: the PNP group was untreated and the PNP ciprofloxacin (CIP) treated group was treated only with CIP intraperitoneally (i.p.) starting on the third day following bacterial inoculation. In the PNP (MB)-treated group, MB was given i.p., and in the PNP MB + CIP-treated group, MB + CIP were administered i.p.. In the sixth week following bacterial inoculation, all rats were sacrificed, and both kidneys of the rats in all groups were examined biochemically and histopathologically for renal scarring. Renal scar was significant in the groups treated with MB alone or MB + CIP combination compared with untreated or antibiotic only groups. Delayed treatment with antibiotics had no effect on scarring. These results suggest that the addition of MB to the delayed antibiotic therapy might be beneficial in preventing PNP-induced oxidative renal tissue damage.
authors: Department of Pediatric Surgery, Faculty of Medicine, Trakya University, Edirne, Turkey. burhanfeyza@yahoo.com
authors: Burhan
authors: B
authors: Aksu
authors: Mustafa
authors: M
authors: Inan
authors: Mehmet
authors: M
authors: Kanter
authors: Fulya
authors: F
authors: Oz Puyan
authors: Hafize
authors: H
authors: Uzun
authors: Gulay
authors: G
authors: Durmus-Altun
authors: Saban
authors: S
authors: Gurcan
authors: Seval
authors: S
authors: Aydin
authors: Suleyman
authors: S
authors: Ayvaz
authors: Mehmet
authors: M
authors: Pul
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology / Q000627:therapeutic use*; D002921:Cicatrix / Q000517:prevention & control*; D002939:Ciprofloxacin / Q000627:therapeutic use; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000473:pathology; D048168:Escherichia coli K12 / Q000472:pathogenicity; D005260:Female; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology*; D008751:Methylene Blue / Q000494:pharmacology / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy* / Q000209:etiology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D002939:Ciprofloxacin; D008751:Methylene Blue